A recent Cleveland Clinic study revealed for the first time that the molecular features of a low-grade tumor as measured by genomic testing, rather than the amount of tumor present on biopsy, can identify which cancers should be treated and which are safe to watch.
Research investigating the impact of tumor sequencing on treatment decisions in metastatic colorectal cancer patients finds genomic profiling enhances therapeutic options.
Early Cleveland Clinic findings show that expanded cancer genomic testing can be done quickly and often identifies potential therapeutic targets. Clinical trials are evaluating compounds specifically aimed at those targets.
Cleveland Clinic oncologists are evaluating a genomic test that looks for 236 genes implicated in cancer. A key question the clinical study will try to answer is how well the broad genomic screen works in real-world settings.